secwatch / observer
8-K filed May 8, 2023, 7:59 PM ET ticker ZVRA CIK 0001434647
leadership confidence high sentiment neutral materiality 0.55

Zevra CEO Richard Pascoe resigns effective June 1, 2023; two directors not standing for re-election

ZEVRA THERAPEUTICS, INC.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew R. Plooster

Director
ZVRA · ZEVRA THERAPEUTICS, INC.
Filed
May 8, 2023, 7:59 PM ET
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
Departed

Richard W. Pascoe

Chief Executive Officer
ZVRA · ZEVRA THERAPEUTICS, INC.
Effective
2023-06-01
Filed
May 8, 2023, 7:59 PM ET
On May 5, 2023, Richard W. Pascoe, the Chief Executive Officer of Zevra Therapeutics, Inc. (the “Company” or “Zevra”), resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.
Departed

Joseph B. Saluri

Director
ZVRA · ZEVRA THERAPEUTICS, INC.
Filed
May 8, 2023, 7:59 PM ET
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew R. Plooster departed as Director at ZEVRA THERAPEUTICS, INC..

Action
will not stand for re-election and will resign
Role
Director
Exact text from the filing
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On May 5, 2023, Richard W. Pascoe, the Chief Executive Officer of Zevra Therapeutics, Inc. (the “Company” or “Zevra”), resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph B. Saluri departed as Director at ZEVRA THERAPEUTICS, INC..

Action
will not stand for re-election and will resign
Role
Director
Exact text from the filing
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001437749-23-012904
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.